AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. The Pollinex Quattro (PQ) platform, an ultra-short-course subcutaneous allergy immunotherapy (SCIT), continues to gain market share despite its availability in the EU on a ‘named-patient’ (NP) basis only. Several products are in clinical development, with the aim of moving the platform to full registration under the new regulatory framework. AGY has issued a positive trading update highli
01 Jul 2019
Successful legal outcome removes uncertainty
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Successful legal outcome removes uncertainty
Allergy Therapeutics plc (AGY:LON) | 3.1 0 (-1.4%) | Mkt Cap: 146.6m
- Published:
01 Jul 2019 -
Author:
Martin Hall -
Pages:
7
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. The Pollinex Quattro (PQ) platform, an ultra-short-course subcutaneous allergy immunotherapy (SCIT), continues to gain market share despite its availability in the EU on a ‘named-patient’ (NP) basis only. Several products are in clinical development, with the aim of moving the platform to full registration under the new regulatory framework. AGY has issued a positive trading update highli